Liang Der-Cherng, Chen Shih-Hsiang, Liu Hsi-Che, Yang Chao-Ping, Yeh Ting-Chi, Jaing Tang-Her, Hung Iou-Jih, Hou Jen-Yin, Lin Tung-Huei, Lin Chun-Hui, Shih Lee-Yung
Division of Pediatric Hematology-Oncology, Mackay Memorial Hospital and Mackay Medical College, Taipei, Taiwan.
Division of Hematology-Oncology, Department of Pediatrics, Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Pediatr Blood Cancer. 2018 Feb;65(2). doi: 10.1002/pbc.26786. Epub 2017 Aug 29.
We aimed to investigate the frequencies and the association with genetic/cytogenetic abnormalities as well as prognostic relevance of RAS pathway mutations in Taiwanese children with B-precursor acute lymphoblastic leukemia (ALL), the largest cohort in Asians.
Between 1995 and 2012, marrow samples at diagnosis from 535 children were studied for NRAS, KRAS, and PTPN11 mutations. The mutational status of each gene was correlated with the clinico-hematological features, recurrent genetic abnormalities, and outcomes for those treated with TPOG-ALL-2002 protocol (n = 346).
The frequencies of NRAS, KRAS, and PTPN11 mutations were 10.8% (57/530), 10.2% (54/530), and 3.0% (16/526), respectively. NRAS mutations were associated with a higher frequency of hyperdiploidy (P = 0.01) and lower frequency of ETV6-RUNX1 (P < 0.01), whereas KRAS mutations were associated with younger age (P < 0.01), a higher frequency of KMT2A rearranged (P < 0.01) but no significant difference if infants with ALL were excluded, and inferior event-free survival (66.6% vs. 80.5%, P = 0.04). None of patients with TCF3-PBX1 had KRAS mutation (P = 0.02).
Our study showed that the frequency of KRAS mutations in Taiwan was significantly higher than that reported in Caucasians. The occurrence of RAS pathway mutations was associated with recurrent genetic/cytogenetic abnormalities in pediatric B-precursor ALL.
我们旨在调查台湾B前体急性淋巴细胞白血病(ALL)儿童中RAS通路突变的频率、与基因/细胞遗传学异常的关联以及预后相关性,这是亚洲最大的队列研究。
在1995年至2012年期间,对535名儿童诊断时的骨髓样本进行NRAS、KRAS和PTPN11突变研究。每个基因的突变状态与临床血液学特征、复发性基因异常以及接受TPOG-ALL-2002方案治疗的患者(n = 346)的预后相关。
NRAS、KRAS和PTPN11突变的频率分别为10.8%(57/530)、10.2%(54/530)和3.0%(16/526)。NRAS突变与高倍体频率较高(P = 0.01)和ETV6-RUNX1频率较低(P < 0.01)相关,而KRAS突变与年龄较小(P < 0.01)、KMT2A重排频率较高(P < 0.01)相关,但排除ALL婴儿后无显著差异,且无事件生存期较差(66.6%对80.5%,P = 0.04)。TCF3-PBX1患者均无KRAS突变(P = 0.02)。
我们的研究表明,台湾KRAS突变的频率显著高于白种人报道的频率。RAS通路突变的发生与儿童B前体ALL的复发性基因/细胞遗传学异常相关。